Price to Book Value (P/BV)
since 2005
Paying user area
Try for free
Illumina Inc. pages available for free this week:
- Common-Size Income Statement
- Common-Size Balance Sheet: Liabilities and Stockholders’ Equity
- Analysis of Profitability Ratios
- Analysis of Long-term (Investment) Activity Ratios
- DuPont Analysis: Disaggregation of ROE, ROA, and Net Profit Margin
- Enterprise Value to EBITDA (EV/EBITDA)
- Price to FCFE (P/FCFE)
- Operating Profit Margin since 2005
- Return on Assets (ROA) since 2005
- Total Asset Turnover since 2005
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Illumina Inc. for $22.49.
This is a one-time payment. There is no automatic renewal.
We accept:
Calculation
Illumina Inc., P/BV, long-term trends, calculation
| P/BV | = | Share price1, 2, 3 | ÷ | Book value per share1 (BVPS) | BVPS1 | = | Illumina stockholders’ equity1 (in millions) |
÷ | No. shares of common stock outstanding2 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 17, 2021 | = | ÷ | = | ÷ | |||||||
| Feb 11, 2020 | = | ÷ | = | ÷ | |||||||
| Feb 12, 2019 | = | ÷ | = | ÷ | |||||||
| Feb 13, 2018 | = | ÷ | = | ÷ | |||||||
| Feb 14, 2017 | = | ÷ | = | ÷ | |||||||
| Mar 2, 2016 | = | ÷ | = | ÷ | |||||||
| Feb 18, 2015 | = | ÷ | = | ÷ | |||||||
| Feb 18, 2014 | = | ÷ | = | ÷ | |||||||
| Feb 15, 2013 | = | ÷ | = | ÷ | |||||||
| Feb 24, 2012 | = | ÷ | = | ÷ | |||||||
| Feb 28, 2011 | = | ÷ | = | ÷ | |||||||
| Feb 26, 2010 | = | ÷ | = | ÷ | |||||||
| Feb 26, 2009 | = | ÷ | = | ÷ | |||||||
| Feb 26, 2008 | = | ÷ | = | ÷ | |||||||
| Feb 28, 2007 | = | ÷ | = | ÷ | |||||||
| Mar 6, 2006 | = | ÷ | = | ÷ |
Based on: 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-29), 10-K (reporting date: 2018-12-30), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2017-01-01), 10-K (reporting date: 2016-01-03), 10-K (reporting date: 2014-12-28), 10-K (reporting date: 2013-12-29), 10-K (reporting date: 2012-12-30), 10-K (reporting date: 2012-01-01), 10-K (reporting date: 2011-01-02), 10-K (reporting date: 2010-01-03), 10-K (reporting date: 2008-12-28), 10-K (reporting date: 2007-12-30), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2006-01-01).
1 US$
2 Data adjusted for splits and stock dividends.
3 Closing price as at the filing date of Illumina Inc. Annual Report.
- Share Price Trend
- The share price exhibited notable volatility over the period analyzed. Starting at $12.79 in 2006, there was a general upward trajectory with significant jumps at certain points, reaching as high as $69.40 by 2011. After a dip in 2012 and 2013, the share price surged dramatically from 2014 onwards, culminating in a peak of $494.24 by early 2021. This indicates periods of strong market optimism and investor confidence, particularly from 2014 onward.
- Book Value Per Share (BVPS) Trend
- BVPS demonstrated consistent growth throughout the years, beginning at $0.88 in 2006 and increasing steadily to $32.17 in 2021. This reflects a steady accumulation of net assets per share, indicating an improving underlying equity base. Despite some fluctuations, the overall upward trend in BVPS suggests sustained internal value creation by the company.
- Price-to-Book Value (P/BV) Ratio Trend
- The P/BV ratio showed considerable fluctuations, highlighting changes in market valuation relative to book value. Initially extremely high at 14.56 in 2006, it dropped significantly by 2009 to 4.59, suggesting a period when the share price was more closely aligned with book value. Thereafter, the ratio fluctuated, with peaks in 2014 and 2015 exceeding 19, reflecting heightened investor expectations and potentially overvaluation relative to net assets. Towards 2021, the ratio rose again to 15.36, implying that the market valued the company's shares at a considerable premium over book value.
- Overall Insights
- The data reveals an entity experiencing substantial growth in intrinsic book value, combined with periods of elevated market valuation as reflected by share price surges and high P/B multiples. The divergence between share price increases and more moderate BVPS growth at times suggests speculative market trends or investor expectations beyond current net asset values. The company's valuation multiples remained elevated in the latter years, indicating persistent confidence or growth prospects appreciated by the market despite the premium paid relative to book value.
Comparison to Competitors
Illumina Inc., P/BV, long-term trends, comparison to competitors
| Illumina Inc. | AbbVie Inc. | Amgen Inc. | Bristol-Myers Squibb Co. | Danaher Corp. | Eli Lilly & Co. | Gilead Sciences Inc. | Johnson & Johnson | Merck & Co. Inc. | Pfizer Inc. | Regeneron Pharmaceuticals Inc. | Thermo Fisher Scientific Inc. | Vertex Pharmaceuticals Inc. | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 17, 2021 | |||||||||||||
| Feb 11, 2020 | |||||||||||||
| Feb 12, 2019 | |||||||||||||
| Feb 13, 2018 | |||||||||||||
| Feb 14, 2017 | |||||||||||||
| Mar 2, 2016 | |||||||||||||
| Feb 18, 2015 | |||||||||||||
| Feb 18, 2014 | |||||||||||||
| Feb 15, 2013 | |||||||||||||
| Feb 24, 2012 | |||||||||||||
| Feb 28, 2011 | |||||||||||||
| Feb 26, 2010 | |||||||||||||
| Feb 26, 2009 | |||||||||||||
| Feb 26, 2008 | |||||||||||||
| Feb 28, 2007 | |||||||||||||
| Mar 6, 2006 |
Based on: 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-29), 10-K (reporting date: 2018-12-30), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2017-01-01), 10-K (reporting date: 2016-01-03), 10-K (reporting date: 2014-12-28), 10-K (reporting date: 2013-12-29), 10-K (reporting date: 2012-12-30), 10-K (reporting date: 2012-01-01), 10-K (reporting date: 2011-01-02), 10-K (reporting date: 2010-01-03), 10-K (reporting date: 2008-12-28), 10-K (reporting date: 2007-12-30), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2006-01-01).
Comparison to Sector (Pharmaceuticals, Biotechnology & Life Sciences)
Illumina Inc., P/BV, long-term trends, comparison to sector (pharmaceuticals, biotechnology & life sciences)
| Illumina Inc. | Pharmaceuticals, Biotechnology & Life Sciences | |
|---|---|---|
| Feb 17, 2021 | ||
| Feb 11, 2020 | ||
| Feb 12, 2019 | ||
| Feb 13, 2018 | ||
| Feb 14, 2017 | ||
| Mar 2, 2016 | ||
| Feb 18, 2015 | ||
| Feb 18, 2014 | ||
| Feb 15, 2013 | ||
| Feb 24, 2012 | ||
| Feb 28, 2011 | ||
| Feb 26, 2010 | ||
| Feb 26, 2009 | ||
| Feb 26, 2008 | ||
| Feb 28, 2007 | ||
| Mar 6, 2006 |
Based on: 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-29), 10-K (reporting date: 2018-12-30), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2017-01-01), 10-K (reporting date: 2016-01-03), 10-K (reporting date: 2014-12-28), 10-K (reporting date: 2013-12-29), 10-K (reporting date: 2012-12-30), 10-K (reporting date: 2012-01-01), 10-K (reporting date: 2011-01-02), 10-K (reporting date: 2010-01-03), 10-K (reporting date: 2008-12-28), 10-K (reporting date: 2007-12-30), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2006-01-01).
Comparison to Industry (Health Care)
Illumina Inc., P/BV, long-term trends, comparison to industry (health care)
| Illumina Inc. | Health Care | |
|---|---|---|
| Feb 17, 2021 | ||
| Feb 11, 2020 | ||
| Feb 12, 2019 | ||
| Feb 13, 2018 | ||
| Feb 14, 2017 | ||
| Mar 2, 2016 | ||
| Feb 18, 2015 | ||
| Feb 18, 2014 | ||
| Feb 15, 2013 | ||
| Feb 24, 2012 | ||
| Feb 28, 2011 | ||
| Feb 26, 2010 | ||
| Feb 26, 2009 | ||
| Feb 26, 2008 | ||
| Feb 28, 2007 | ||
| Mar 6, 2006 |
Based on: 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-29), 10-K (reporting date: 2018-12-30), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2017-01-01), 10-K (reporting date: 2016-01-03), 10-K (reporting date: 2014-12-28), 10-K (reporting date: 2013-12-29), 10-K (reporting date: 2012-12-30), 10-K (reporting date: 2012-01-01), 10-K (reporting date: 2011-01-02), 10-K (reporting date: 2010-01-03), 10-K (reporting date: 2008-12-28), 10-K (reporting date: 2007-12-30), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2006-01-01).